BDBM108112 US8598206, Table 6, 21

SMILES NC(=N)c1ccc(CNC(=O)[C@H](CCC2CCNCC2)NC(=O)[C@@H](CCc2cc[n+]([O-])cc2)NS(=O)(=O)Cc2ccccc2)cc1

InChI Key InChIKey=CKZGCUFXVIRNEZ-XZWHSSHBSA-N

Data  9 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 108112   

TargetPlasminogen(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCoagulation factor X(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  120nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVitamin K-dependent protein C(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  250nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCoagulation factor XI(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  2.50E+3nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetComplement C1s subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  4.20E+3nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTranscription initiation factor IIA subunit 1(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  9.00E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetComplement C1r subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi: >5.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi: >1.00E+5nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In DepthDetails
US Patent